Will biopharma deal-making brave the headwinds or retreat to 'wait-and-see'?
Following a record-breaking year for deal-makers, 2016 isn't exactly off to the races. The drug pricing debate, magnified through the lens of a contentious Presidential campaign, and mounting pressure on the industry's blue chips to improve performance in the midst of a volatile stock market have placed heavy demands on partnering activity. In a super session on the final day of the BIO International Convention, a panel of veteran deal-makers debated whether big biopharmas will take a wait-and-see approach or throw caution to the wind and forge ahead with partnering and M&A.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST